Trade MiMedx - MDXG CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
MiMedx Group Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 7.74 |
Open* | 7.76 |
1-Year Change* | 153.59% |
Day's Range* | 7.69 - 7.81 |
52 wk Range | 2.43-8.60 |
Average Volume (10 days) | 743.82K |
Average Volume (3 months) | 13.26M |
Market Cap | 839.08M |
P/E Ratio | -100.00K |
Shares Outstanding | 116.38M |
Revenue | 309.02M |
EPS | -0.02 |
Dividend (Yield %) | N/A |
Beta | 1.62 |
Next Earnings Date | Feb 26, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 29, 2023 | 7.74 | 0.01 | 0.13% | 7.73 | 7.96 | 7.73 |
Nov 28, 2023 | 7.86 | 0.19 | 2.48% | 7.67 | 7.91 | 7.67 |
Nov 27, 2023 | 7.89 | 0.47 | 6.33% | 7.42 | 7.96 | 7.41 |
Nov 24, 2023 | 7.53 | 0.03 | 0.40% | 7.50 | 7.70 | 7.46 |
Nov 22, 2023 | 7.53 | 0.54 | 7.73% | 6.99 | 7.61 | 6.98 |
Nov 21, 2023 | 7.19 | 0.17 | 2.42% | 7.02 | 7.23 | 6.91 |
Nov 20, 2023 | 7.13 | 0.32 | 4.70% | 6.81 | 7.18 | 6.72 |
Nov 17, 2023 | 7.02 | 0.51 | 7.83% | 6.51 | 7.09 | 6.51 |
Nov 16, 2023 | 6.67 | 0.28 | 4.38% | 6.39 | 6.70 | 6.39 |
Nov 15, 2023 | 6.57 | 0.19 | 2.98% | 6.38 | 6.78 | 6.38 |
Nov 14, 2023 | 6.66 | 0.47 | 7.59% | 6.19 | 6.68 | 6.19 |
Nov 13, 2023 | 6.13 | 0.40 | 6.98% | 5.73 | 6.19 | 5.72 |
Nov 10, 2023 | 5.91 | 0.25 | 4.42% | 5.66 | 5.97 | 5.48 |
Nov 9, 2023 | 5.67 | -0.37 | -6.13% | 6.04 | 6.11 | 5.65 |
Nov 8, 2023 | 6.06 | -0.28 | -4.42% | 6.34 | 6.47 | 6.03 |
Nov 7, 2023 | 6.45 | -0.24 | -3.59% | 6.69 | 6.71 | 6.35 |
Nov 6, 2023 | 6.66 | -0.04 | -0.60% | 6.70 | 6.74 | 6.49 |
Nov 3, 2023 | 6.78 | 0.44 | 6.94% | 6.34 | 6.91 | 6.33 |
Nov 2, 2023 | 6.46 | 0.06 | 0.94% | 6.40 | 6.60 | 6.32 |
Nov 1, 2023 | 6.42 | 0.04 | 0.63% | 6.38 | 6.44 | 6.17 |
MiMedx Events
Time (UTC) | Country | Event |
---|---|---|
Monday, February 26, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2023 MiMedx Group Inc Earnings Release Q4 2023 MiMedx Group Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 267.841 | 258.615 | 248.234 | 299.255 | 359.111 |
Revenue | 267.841 | 258.615 | 248.234 | 299.255 | 359.111 |
Cost of Revenue, Total | 48.316 | 43.283 | 39.33 | 43.081 | 36.386 |
Gross Profit | 219.525 | 215.332 | 208.904 | 256.174 | 322.725 |
Total Operating Expense | 292.812 | 263.65 | 301.833 | 320.415 | 363.035 |
Selling/General/Admin. Expenses, Total | 207.546 | 196.081 | 177.606 | 193.982 | 252.628 |
Research & Development | 22.543 | 17.046 | 11.371 | 10.782 | 15.765 |
Depreciation / Amortization | 2.23 | 3.396 | 4.833 | 5.62 | 6.934 |
Unusual Expense (Income) | 12.177 | 3.844 | 68.693 | 66.95 | 51.322 |
Operating Income | -24.971 | -5.035 | -53.599 | -21.16 | -3.924 |
Interest Income (Expense), Net Non-Operating | -5.016 | -4.98 | -7.941 | -4.708 | 0.527 |
Net Income Before Taxes | -29.991 | -10.038 | -61.543 | -25.585 | -3.397 |
Net Income After Taxes | -30.197 | -10.285 | -49.284 | -25.58 | -29.979 |
Net Income Before Extra. Items | -30.197 | -10.285 | -49.284 | -25.58 | -29.979 |
Net Income | -30.197 | -10.285 | -49.284 | -25.58 | -29.979 |
Income Available to Common Excl. Extra. Items | -36.777 | -16.421 | -83.328 | -25.58 | -29.979 |
Income Available to Common Incl. Extra. Items | -36.777 | -16.421 | -83.328 | -25.58 | -29.979 |
Diluted Net Income | -36.777 | -16.421 | -83.328 | -25.58 | -29.979 |
Diluted Weighted Average Shares | 112.909 | 110.353 | 108.257 | 106.946 | 105.596 |
Diluted EPS Excluding Extraordinary Items | -0.32572 | -0.1488 | -0.76972 | -0.23919 | -0.2839 |
Diluted Normalized EPS | -0.25562 | -0.12616 | -0.35727 | 0.16772 | 0.03201 |
Total Extraordinary Items | |||||
Other, Net | -0.004 | -0.023 | -0.003 | 0.283 | |
Total Adjustments to Net Income | -6.58 | -6.136 | -34.044 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 81.257 | 71.676 | 74.375 | 67.689 | 66.883 |
Revenue | 81.257 | 71.676 | 74.375 | 67.689 | 66.883 |
Cost of Revenue, Total | 13.583 | 12.419 | 14.369 | 12.188 | 11.823 |
Gross Profit | 67.674 | 59.257 | 60.006 | 55.501 | 55.06 |
Total Operating Expense | 78.469 | 75.057 | 73.308 | 74.792 | 76.519 |
Selling/General/Admin. Expenses, Total | 51.925 | 52.279 | 49.951 | 53.475 | 55.793 |
Research & Development | 8.497 | 6.496 | 5.4 | 5.953 | 5.512 |
Depreciation / Amortization | 0.191 | 0.19 | 0.182 | 0.175 | 0.173 |
Unusual Expense (Income) | 4.273 | 3.673 | 3.406 | 3.001 | 3.218 |
Operating Income | 2.788 | -3.381 | 1.067 | -7.103 | -9.636 |
Interest Income (Expense), Net Non-Operating | -1.63 | -1.553 | -1.45 | -1.27 | -1.17 |
Other, Net | -0.032 | 0.002 | -0.003 | 0 | 0 |
Net Income Before Taxes | 1.126 | -4.932 | -0.386 | -8.373 | -10.806 |
Net Income After Taxes | 1.2 | -4.983 | -0.414 | -8.426 | -10.868 |
Net Income Before Extra. Items | 1.2 | -4.983 | -0.414 | -8.426 | -10.868 |
Net Income | 1.2 | -4.983 | -0.414 | -8.426 | -10.868 |
Total Adjustments to Net Income | -1.728 | -1.684 | -1.696 | -1.67 | -1.628 |
Income Available to Common Excl. Extra. Items | -0.528 | -6.667 | -2.11 | -10.096 | -12.496 |
Income Available to Common Incl. Extra. Items | -0.528 | -6.667 | -2.11 | -10.096 | -12.496 |
Diluted Net Income | -0.528 | -6.667 | -2.11 | -10.096 | -12.496 |
Diluted Weighted Average Shares | 115.866 | 114.399 | 113.685 | 113.448 | 112.868 |
Diluted EPS Excluding Extraordinary Items | -0.00456 | -0.05828 | -0.01856 | -0.08899 | -0.11071 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.01941 | -0.03741 | 0.00091 | -0.0718 | -0.09218 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 134.198 | 148.523 | 160.617 | 123.245 | 74.049 |
Cash and Short Term Investments | 65.95 | 87.083 | 95.812 | 69.069 | 45.118 |
Cash & Equivalents | 65.95 | 87.083 | 95.812 | 69.069 | 45.118 |
Short Term Investments | |||||
Total Receivables, Net | 43.788 | 41.096 | 45.468 | 32.345 | 0.454 |
Accounts Receivable - Trade, Net | 43.084 | 40.353 | 35.423 | 32.327 | |
Total Inventory | 13.183 | 11.389 | 10.361 | 9.104 | 15.986 |
Prepaid Expenses | 8.646 | 6.146 | 5.605 | 6.669 | 6.673 |
Other Current Assets, Total | 2.631 | 2.809 | 3.371 | 6.058 | 5.818 |
Total Assets | 171.43 | 187.929 | 202.032 | 167.166 | 122.844 |
Property/Plant/Equipment, Total - Net | 11.256 | 13.861 | 15.06 | 15.725 | 17.424 |
Property/Plant/Equipment, Total - Gross | 47.183 | 46.739 | 44.558 | 39.702 | 35.782 |
Accumulated Depreciation, Total | -35.927 | -32.878 | -29.498 | -23.977 | -18.587 |
Goodwill, Net | 19.976 | 19.976 | 19.976 | 19.976 | 19.976 |
Intangibles, Net | 5.852 | 5.383 | 6.004 | 7.777 | 9.608 |
Other Long Term Assets, Total | 0.148 | 0.186 | 0.375 | 0.443 | 1.787 |
Total Current Liabilities | 43.557 | 42.357 | 59.162 | 67.322 | 71.547 |
Accounts Payable | 8.847 | 7.385 | 8.765 | 8.71 | 14.864 |
Accrued Expenses | 34.267 | 34.61 | 50.103 | 54.631 | 54.866 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.443 | 0.362 | 0.294 | 0.231 | 1.817 |
Total Liabilities | 96.924 | 95.353 | 110.614 | 132.768 | 73.189 |
Total Long Term Debt | 48.594 | 48.127 | 47.697 | 61.906 | 0 |
Other Liabilities, Total | 4.773 | 4.869 | 3.755 | 3.54 | 1.642 |
Total Equity | 74.506 | 92.576 | 91.418 | 34.398 | 49.655 |
Redeemable Preferred Stock | 92.494 | 92.494 | 91.568 | 0 | 0 |
Common Stock | 0.114 | 0.113 | 0.113 | 0.113 | 0.113 |
Additional Paid-In Capital | 173.804 | 165.695 | 158.61 | 147.231 | 164.744 |
Retained Earnings (Accumulated Deficit) | -191.906 | -161.709 | -151.424 | -102.14 | -76.56 |
Treasury Stock - Common | 0 | -4.017 | -7.449 | -10.806 | -38.642 |
Total Liabilities & Shareholders’ Equity | 171.43 | 187.929 | 202.032 | 167.166 | 122.844 |
Total Common Shares Outstanding | 113.705 | 111.925 | 110.93 | 110.819 | 109.099 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 3.75 | |||
Long Term Debt | 48.594 | 48.127 | 47.697 | 61.906 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 154.502 | 141.223 | 131.702 | 134.198 | 136.04 |
Cash and Short Term Investments | 81.164 | 68.652 | 61.221 | 65.95 | 73.217 |
Cash & Equivalents | 81.164 | 68.652 | 61.221 | 65.95 | 73.217 |
Total Receivables, Net | 49.005 | 48.963 | 44.694 | 43.788 | 41.586 |
Accounts Receivable - Trade, Net | 49.005 | 48.963 | 44.694 | 43.084 | 40.83 |
Total Inventory | 19.068 | 16.815 | 14.657 | 13.183 | 13.976 |
Prepaid Expenses | 2.954 | 3.683 | 8.824 | 8.646 | 4.679 |
Other Current Assets, Total | 2.311 | 3.11 | 2.306 | 2.631 | 2.582 |
Total Assets | 189.022 | 176.378 | 168.159 | 171.43 | 172.798 |
Property/Plant/Equipment, Total - Net | 9.535 | 10.003 | 10.628 | 11.256 | 11.64 |
Property/Plant/Equipment, Total - Gross | 47.47 | 47.286 | 47.268 | 47.183 | 46.771 |
Accumulated Depreciation, Total | -37.935 | -37.283 | -36.64 | -35.927 | -35.131 |
Goodwill, Net | 19.441 | 19.441 | 19.976 | 19.976 | 19.976 |
Intangibles, Net | 5.395 | 5.565 | 5.706 | 5.852 | 4.992 |
Other Long Term Assets, Total | 0.149 | 0.146 | 0.147 | 0.148 | 0.15 |
Total Current Liabilities | 43.627 | 44.46 | 40.87 | 43.557 | 45.858 |
Accounts Payable | 9.17 | 8.15 | 7.823 | 8.847 | 8.82 |
Accrued Expenses | 32.603 | 34.247 | 31.253 | 32.876 | 35.076 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 1.854 | 2.063 | 1.794 | 1.834 | 1.962 |
Total Liabilities | 95.198 | 96.55 | 93.611 | 96.924 | 99.824 |
Total Long Term Debt | 48.966 | 48.838 | 48.714 | 48.594 | 48.475 |
Long Term Debt | 48.966 | 48.838 | 48.714 | 48.594 | 48.475 |
Capital Lease Obligations | |||||
Other Liabilities, Total | 2.605 | 3.252 | 4.027 | 4.773 | 5.491 |
Total Equity | 93.824 | 79.828 | 74.548 | 74.506 | 72.974 |
Redeemable Preferred Stock | 92.494 | 92.494 | 92.494 | 92.494 | 92.494 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.116 | 0.116 | 0.115 | 0.114 | 0.114 |
Additional Paid-In Capital | 188.369 | 182.907 | 178.829 | 173.804 | 171.865 |
Retained Earnings (Accumulated Deficit) | -187.155 | -195.689 | -196.889 | -191.906 | -191.492 |
Treasury Stock - Common | -0.001 | 0 | -0.007 | ||
Total Liabilities & Shareholders’ Equity | 189.022 | 176.378 | 168.159 | 171.43 | 172.798 |
Total Common Shares Outstanding | 116.36 | 116.109 | 115.38 | 113.705 | 113.668 |
Total Preferred Shares Outstanding | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -30.197 | -10.285 | -49.284 | -25.58 | -29.979 |
Cash From Operating Activities | -17.893 | -1.982 | -30.263 | -39.412 | 35.796 |
Cash From Operating Activities | 3.345 | 4.363 | 5.782 | 6.546 | 5.882 |
Amortization | 0.701 | 0.82 | 1.073 | 1.039 | 1.034 |
Deferred Taxes | 0 | 0 | 25.541 | ||
Non-Cash Items | 17.287 | 17.197 | 27.855 | -1.364 | 14.715 |
Cash Taxes Paid | 0.181 | 0.169 | 0.208 | 0.308 | 0.859 |
Changes in Working Capital | -9.029 | -14.077 | -15.689 | -20.053 | 18.603 |
Cash From Investing Activities | -2.66 | -3.395 | -4.555 | 0.504 | -9.22 |
Capital Expenditures | -2.684 | -3.47 | -4.555 | -2.218 | -10.028 |
Other Investing Cash Flow Items, Total | 0.024 | 0.075 | 0 | 2.722 | 0.808 |
Cash From Financing Activities | -0.58 | -3.352 | 61.561 | 62.859 | -8.934 |
Financing Cash Flow Items | -1.19 | -4.751 | -14.478 | -8.124 | -4.914 |
Issuance (Retirement) of Stock, Net | 0.651 | 1.437 | 100.411 | 0.108 | -4.017 |
Issuance (Retirement) of Debt, Net | -0.041 | -0.038 | -24.372 | 70.875 | -0.003 |
Net Change in Cash | -21.133 | -8.729 | 26.743 | 23.951 | 17.642 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.983 | -30.197 | -29.783 | -21.357 | -10.489 |
Cash From Operating Activities | -4.048 | -17.893 | -12.269 | -13.228 | -10.223 |
Cash From Operating Activities | 0.714 | 3.345 | 2.549 | 1.718 | 0.86 |
Amortization | 0.19 | 0.701 | 0.519 | 0.345 | 0.172 |
Non-Cash Items | 4.762 | 17.287 | 14.946 | 11.687 | 4.412 |
Cash Taxes Paid | 0 | 0.181 | 0.184 | 0.184 | 0 |
Changes in Working Capital | -4.731 | -9.029 | -0.5 | -5.621 | -5.178 |
Cash From Investing Activities | -0.677 | -2.66 | -0.951 | -0.577 | -0.148 |
Capital Expenditures | -0.677 | -2.684 | -0.975 | -0.601 | -0.172 |
Other Investing Cash Flow Items, Total | 0 | 0.024 | 0.024 | 0.024 | 0.024 |
Cash From Financing Activities | -0.004 | -0.58 | -0.646 | -0.776 | -1.036 |
Financing Cash Flow Items | 0 | -1.19 | -1.191 | -1.191 | -1.191 |
Issuance (Retirement) of Stock, Net | 0 | 0.651 | 0.574 | 0.437 | 0.166 |
Issuance (Retirement) of Debt, Net | -0.004 | -0.041 | -0.029 | -0.022 | -0.011 |
Net Change in Cash | -4.729 | -21.133 | -13.866 | -14.581 | -11.407 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Prescience Point Capital Management LLC | Investment Advisor/Hedge Fund | 6.5478 | 7602577 | 0 | 2022-06-15 | |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.1989 | 7197496 | 90897 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.313 | 6168828 | 79021 | 2023-06-30 | LOW |
Paradigm Capital Management, Inc. | Investment Advisor/Hedge Fund | 2.9975 | 3480400 | 29998 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 2.8972 | 3363925 | -385270 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 2.0078 | 2331277 | 132740 | 2023-06-30 | LOW |
Wright (Timothy R) | Individual Investor | 1.4739 | 1711324 | 0 | 2023-04-11 | |
Richmond Brothers, Inc. | Investment Advisor | 1.3664 | 1586500 | -168627 | 2023-06-30 | MED |
Millennium Management LLC | Hedge Fund | 1.229 | 1427032 | 1373237 | 2023-06-30 | HIGH |
Cannell Capital, LLC | Hedge Fund | 0.9476 | 1100256 | 696594 | 2023-06-30 | LOW |
Charles Schwab Investment Management, Inc. | Investment Advisor | 0.8533 | 990717 | 57265 | 2023-06-30 | LOW |
D. E. Shaw & Co., L.P. | Hedge Fund | 0.8397 | 974930 | 443200 | 2023-06-30 | MED |
Two Sigma Investments, LP | Hedge Fund | 0.8203 | 952496 | 672384 | 2023-06-30 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7781 | 903499 | 22649 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.7755 | 900385 | 20800 | 2023-06-30 | HIGH |
Royce Investment Partners | Investment Advisor/Hedge Fund | 0.7542 | 875700 | 33700 | 2023-06-30 | LOW |
Federated MDTA LLC | Investment Advisor/Hedge Fund | 0.7288 | 846250 | -106958 | 2023-06-30 | HIGH |
Kanen Wealth Management, LLC | Investment Advisor/Hedge Fund | 0.7191 | 834912 | 834912 | 2023-06-30 | MED |
Morgan Stanley & Co. LLC | Research Firm | 0.6972 | 809462 | 460236 | 2023-06-30 | MED |
Divisadero Street Capital Management, LP | Investment Advisor/Hedge Fund | 0.689 | 800000 | 800000 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
MiMedx Company profile
About MiMedx Group Inc
MiMedx Group, Inc. is utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts for multiple sectors of healthcare. The Company is focused on addressing the needs of patients with acute and chronic non-healing wounds, and a late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. The Company’s platform technologies include AmnioFix, EpiFix, EpiCord, AmnioCord and AmnioFill. Its AmnioFix and EpiFix are its tissue allografts derived from the amnion and chorion layers of the human placental membrane. The EpiCord and AmnioCord are tissue allografts derived from umbilical cord tissue. Its AmnioFill is a particulate product comprised of placental connective tissue matrix, derived from the placental disc and placental membranes.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, MiMedx Group Inc revenues increased 4% to $258.6M. Net loss applicable to common stockholders decreased 80% to $16.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investigation, restatement and related decrease of 94% to $3.8M (expense), Loss on extinguishment of debt decrease from $8.2M (expense) to
Equity composition
Common Stock $.001 Par, 03/11, 100M auth., 64,331,910 issd., less 50,000 shs. in Treas. @ $25K. Insiders own approx. 18.35%.
Industry: | Bio Medical Devices |
1775 W Oak Commons Court, Ne
MARIETTA
GEORGIA 30062
US
Income Statement
- Annual
- Quarterly
News

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com